CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MEDEI Issues MedTech Advisory on Mandatory EU Medical Device Regulation

MedTech data management enabler MEDEI ApS today released an Industry Advisory outlining changes and advice that medical device manufacturers can use to comply with the mandatory requirements set out by the new European Union Medical Device Regulation (EU MDR) for a CE-mark approval in the EU.
More medical devices are entering the EU 28 countries than ever before and are transforming healthcare. The EU MDR aims to better regulate the booming MedTech industry and now requires that medical devices sold into the EU adhere to the stringent Regulation by 2020. In vitro diagnostics (IVD) devices will have to comply with the Regulation by 2022.
As the MDR allows “no grandfathering,” manufacturers with products already in use in EU 28 markets will have to re-certify all of their devices and existing compliance documents will have to be aligned with the new MDR/IVDR requirements.
One of the stringent changes in the EU Regulation is the increased focus on clinical evaluation, post market surveillance, and access to data. This places a higher strain on both regulatory and clinical operations.
In the past, common practice within the MedTech industry was to refer to an equivalent (predicate) medical device and its scientific data in order to document clinical effectiveness. In a move to enhance data transparency, the MDR requires all manufacturers to fully document their own device effectiveness, safety and usability.
One of the main focus areas for regulators of EU MDR will be the creation of a Eudamed database and device manufacturers will need the tools necessary to transfer required data into the database.
“Compliance with the EU MDR is uncharted and time-consuming territory for many medical device manufacturers,” said Pall Johannesson, MEDEI’s CEO. ”This Industry Advisory will help them to navigate the EU MDR requirements and support them on their road towards compliance and market access in the ever growing EU MedTech market.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026